SOST and X-linked hypophosphatemia: When compared to control (Ctrl) patients, XLH patients presented with significantly higher expression of sclerostin (SOST), WNT Inhibitory Factor 1 (WIF1), dickkopf 3 (DKK3) a Wnt signaling pathway inhibitor, and Wnt family members 5A and 16 (WNT5A and WNT16) (Fig. 1b).